CytomX looks for $100M in IPO; FDA tells Fibrocell to do a new animal tox study;

@FierceBiotech: Fierce's coverage of the Martin Shkreli saga. More | Follow @FierceBiotech

@JohnCFierce: ICYMI: Novo scores a game-changing diabetes approval, reversing an embarrassing rejection. Article | Follow @JohnCFierce

@DamianFierce: Here's what it's like to try to get Sovaldi in my home town. More from The Atlantic | Follow @DamianFierce

> Looking to jump into a turbulent market, CytomX ($CTMX) set its IPO range at $14 to $16 a shares, looking to sell 6.7 million shares. At the mid-range point that would raise about $100 million. Story

> Fibrocell and Intrexon announced late last week that the FDA wants the company to perform a new animal study on the toxicity of its gene therapy drug FCX-007 before launching a clinical trial. Release

Medical Device News

@FierceMedDev: ICYMI: In latest biopharma-med tech pairing, Teva snaps up respiratory compliance tracker Gecko. More | Follow @FierceMedDev

@StacyALawrence: JDRF, ADA redefine Type 1 diabetes framework to encourage early diagnosis, prevention. Story | Follow @StacyALawrence

@VarunSaxena2: From @FierceMedDev's special report on recalls: Patients struggle to safely use HeartWare's blood pump. More | Follow @VarunSaxena2

@EmilyWFierce: ICYMI from FiercePharma: Shire chalks up victory in Vyvanse patent battle. Article | Follow @EmilyWFierce

> Medtronic to buy stent retriever cover startup Lazarus Effect for $100M. Report

> Intestinal resurfacing procedure to treat diabetes shows promise in early stage trial. Article

Pharma News

@FiercePharma: AKC-funded study IDs similar lymphoma gene types in dogs and people. FierceAnimalHealth story | Follow @FiercePharma

@EricPFierce: ICYMI from FiercePharmaManufacturing: Sun Pharma unit Mutual Pharma recalls 216,766 bottles that may have chemical leaching labels. Story | Follow @EricPFierce

@CarlyHFierce: ICYMI Friday: Roche is 'well placed' for U.S. pricing tussle, CEO says. Report | Follow @CarlyHFierce

> Novo combats talk of insulin price war with 'moderate premium' on brand-new Tresiba. Story

> How much more does the U.S. pay for drugs? Up to 10 times more, report says. Article

Animal Health News

> USDA unveils plan to battle avian flu if it re-emerges this fall. Story

> Sanofi rumored to be weighing Merial spinoff. Report

> Investors trounce Aratana on dashed hopes for canine lymphoma drugs. More

> AKC-funded study IDs similar lymphoma gene types in dogs and people. Story

> Rhizen moves into midstage trial of pill to treat canine lymphoma. Article

Biotech IT News

> BioClinica buys pharmacovigilance outfit to continue evolution. Article

> AstraZeneca opens data vault for cancer combo efficacy prediction challenge. Report

> Feds prioritize researcher access to health data in IT action plan. More

> Bayer pairs Genedata Profiler and iRODS to manage omics data analysis. Story

> Venter's HLI strikes low-cost exome sequencing deal to swell data repository. Article

Pharma Marketing News

> International payer report shows U.S. prices almost 10X higher for some meds. Item

> Novartis backs DC Comics graphic novel starring rare-disease hero and his canine sidekick. More

> NEJM: FDA's proposed risk-disclosure guidelines still aren't enough. Story

> Don't be quick to peg Merck's Keytruda in second place for NSCLC, analyst says. Article

> Not so fast, Hillary. Ad industry will fight with pharma against DTC tax moves. More

Suggested Articles

A TGen-led research team found that increased activity of the gene AEBP1 drives severe liver fibrosis in nonalcoholic steatohepatitis.

Days after announcing its R&D chief was stepping down, Gilead announced it will be buying a few of Novartis’ unwanted early-stage infection assets.

Mallinckrodt is teaming up with Silence Therapeutics to develop an RNAi program aimed at a group of proteins that play a part in promoting inflammation.